Firering Strategic Minerals: From explorer to producer. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,610.50
Bid: 1,610.00
Ask: 1,610.50
Change: -6.00 (-0.37%)
Spread: 0.50 (0.031%)
Open: 1,619.50
High: 1,622.50
Low: 1,609.50
Prev. Close: 1,616.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

European gas inventories back to 10-year average

Wed, 17th Aug 2022 12:19

EUROPEAN GAS INVENTORIES BACK TO 10-YEAR AVERAGE (1117 GMT)

As well as watching trading screens, market players are keeping one eye on European gas supplies as a key metric when weighing up the economic outlook.

According to UBS analysts, European gas storage usage reached its 10-year average at the beginning of August.

As of August 13, storage was 74% full - above last year's level of 61%. At this rate, by the end of October storage levels could be near to 90%, the analysts said in a note.

We can thank liquid natural gas imports for that.

"Imports (of LNG) were up 110% y/y in July and are up 61% y/y YTD which helps to offset low volumes from Russia," they said in a note.

On the other hand, Russian exports have continued to decline.

"In 1H Aug Gazprom exports to Europe stood at ~2.6bcm, down 64% y/y, close to the July daily average."

The analysts said they expect LNG imports in Europe to remain close to first half levels in the second half, but that "risks are to the downside", with potentially more competition from Asian buyers and risk of supply disruptions.

"And these come at a high price, TTF (front-month) approaching €250/MWh today."

STOXX 600: NOT MUCH TO EXPECT FROM EARNINGS NOW (0926 GMT)

The better-than-expected Q2 earnings season, along with a weaker euro, was an essential driver of the summer rally which has lifted the pan-European STOXX 600 over 10% since the June lows.

But as you see can below from the latest Refinitiv I/B/E/S estimates, profit growth is expected to reverse into an earnings recession in 2023:

Moving forward, European stocks, still down over 9% year-to-date, will therefore not likely be able to count on earnings to rebound further this year.

"Q2 earnings have not been the disaster some had predicted, but mixed guidance, high inventories and rising margin pressures offer little comfort", Barclays strategists argued in a note.

So with little to expect from earnings growth, multiples need to expand for the rally to keep on going.

"As slowing growth caps the upside to FY estimates, at best, the bull case for equities relies on renewed P/E expansion", they wrote, calling such a re-rating "elusive".

Then again, as they show in this chart, the low level of European price-to-earnings ratios seems to suggest that there is potentially some upside:

(Julien Ponthus)

STOXX SET FOR SIXTH CONSECUTIVE DAY OF GAINS (0753 GMT)

European shares are into their sixth consecutive day of gains, with the STOXX 600 opening 0.3% higher as markets continue to brush off fears of an energy crisis and recession on the continent.

The financial services sector is leading gains with a 0.88% rise, while healthcare and basic resources are ringing in at the bottom, down 0.22% and 0.35% respectively.

Shares in Uniper are falling 8.2% and are at the bottom of the STOXX 600, unsurprising given the company just reported a hefty 12 billion euro loss in the first half .

Shares in GSK are down 2.1% but stayed above recent lows after the plaintiff in the first lawsuit over the heartburn drug Zantac scheduled to go to trial agreed to drop his case .

At the top of the index is Swiss laboratory instruments maker Tecan Group, surging 12% after a H1 beat and raising its FY sales outlook.

MORE DOOM AND GLOOM LOOMS FOR EUROPE (0640 GMT)

Europeans will be hoping Wednesday’s economic data will provide some respite after a string of negative headlines, but past form suggests they’d be foolish to bet too much on it.

They might even be better off taking a punt on depressing figures, as at least their winnings might provide some small cheer if the bad news arrives.

British consumer price inflation jumped to 10.1% in July, its highest since February 1982, up from an annual rate of 9.4% in June, intensifying the squeeze on households, official figures showed on Wednesday

That’s not good news for British workers who saw earnings for the second quarter adjusted for inflation fall by 4.1%, the biggest drop since records began in 2001, according to data released on Tuesday.

The final reading for Euro zone Q2 GDP is also due on Wednesday, and while preliminary data showed faster than expected growth, even then economists said it might be the economy's last hurrah.

If data from down under offers any clues, they aren’t great.

Earlier on Wednesday New Zealand’s Central Bank signalled a more hawkish tightening path over coming months to restrain stubbornly high inflation, even as it delivered its seventh straight interest rate hike, and Australian wage growth missed forecasts and lagged badly behind inflation.

The kiwi dollar initially climbed on the news before giving up its gains, though the Aussie held onto its losses.

Asian shares eked out small gains in morning trading, following overnight gains on Wall Street, where economic data is less depressing.

Japan was in the lead with the Nikkei up 1%, while MSCI’s broadest index of shares outside Japan rose just 0.2%.

Key developments that could influence markets on Wednesday:

UK Jul CPI, Jul PPI

Euro zone Q2 flash employment, Q2 GDP

US Jul retail sales

US 20-year Treasury auction

Fed Reserve releases minutes from July policy meeting at 1800 GMT

New Zealand's central bank meeting and press conference.

European earnings: Swiss Life, Carlsberg, Uniper

US earnings: Lowe’s, Target, Cisco

(Alun John)

WHAT ECONOMIC GLOOM?: (0629 GMT)

European shares look set for their sixth consecutive day of rises, with futures contracts signalling increases of 0.3% as they track U.S. shares which posted gains on Tuesday after some strong showings from major retailers.

U.S. retail sales data will give a further insight today but in the meantime there are some not so pretty earnings coming out of Europe to contend with.

Danish brewer Carlsberg reported Q2 sales below expectations, while Germany's Uniper, which secured a 15 billion euro bailout last month, reported a net loss of more than 12 billion euros ($12.2 billion) for the first half.

Better news is coming from insurer Swiss Life which has increased its half year net profit by 4%.

On the data front, UK CPI was seen rising to the highest level since 1982, up to 10.1% in July from 9.4% in June.

(Lucy Raitano)

More News
17 Jan 2024 07:31

GSK raises $1.24 bln from latest Haleon stake sale

Jan 17 (Reuters) - GSK has raised 978 million pounds ($1.24 billion) from a discounted sale of a stake in its spun-off consumer healthcare business Haleon, the British drugmaker said on Wednesday.

Read more
16 Jan 2024 17:04

GSK to sell GBP1 billion worth of Haleon shares as trims stake again

(Alliance News) - GSK PLC on Tuesday said it intends to sell around GBP1.00 billion worth of shares in Haleon PLC, as it continues to reduce its shareholding in the Weybridge, Surrey-based consumer healthcare spin-off.

Read more
16 Jan 2024 09:14

LONDON BROKER RATINGS: UBS raises GSK and cuts AstraZeneca

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
16 Jan 2024 08:15

UBS downgrades AstraZeneca to 'sell'

(Sharecast News) - UBS has downgraded AstraZeneca and upgraded rival GSK as part of its latest review of the European pharmaceutical sector.

Read more
16 Jan 2024 07:37

LONDON BRIEFING: UK jobless rate sticks at 4.2% but pay growth slows

(Alliance News) - Stocks in London are called to open lower on Tuesday, following data showing that the UK jobless rate was unchanged at 4.2% as pay growth slowed.

Read more
15 Jan 2024 08:42

Zantac fallout unfairly weighing on GSK, says Shore Capital

(Sharecast News) - Shore Capital has raised its target price and maintained a positive stance on biopharma giant GSK, saying that worries about the potential cost of Zantac litigation are unfairly weighing on the stock.

Read more
10 Jan 2024 09:35

LONDON BROKER RATINGS: BofA cuts Ashtead; UBS likes 3i Group

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
10 Jan 2024 08:25

GSK says Nucala gets green light in China for asthma treatment

(Alliance News) - GSK PLC on Wednesday said Nucala has been approved in China for the treatment of severe asthma.

Read more
10 Jan 2024 07:22

GSK's Nucala gets fresh approval in China

(Sharecast News) - GSK announced on Wednesday that the China National Medical Products Administration (NMPA) has granted approval for 'Nucala', or mepolizumab, as an add-on maintenance treatment for severe eosinophilic asthma in adults and adolescents aged 12 years and older.

Read more
9 Jan 2024 16:22

London close: Stocks finish red after choppy session

(Sharecast News) - London stocks had turned back into the red by the close on Tuesday, with recruitment firms and asset managers pacing the declines after some disappointing corporate updates.

Read more
9 Jan 2024 08:03

TOP NEWS: GSK to buy Aiolos Bio for up to USD1.4 billion

(Alliance News) - GSK PLC on Tuesday said it will acquire asthma drug developer Aiolos Bio Inc for USD1 billion upfront, as well as up to USD400 million in certain success-based milestone payments.

Read more
9 Jan 2024 07:16

GSK buys respiratory drug maker Aiolos for $1bn

(Sharecast News) - GSK said it was buying Aiolos, a clinical-stage biopharmaceutical company focused on treatment of respiratory and inflammatory conditions, for up to $1.4bn (£1.1bn).

Read more
8 Jan 2024 23:39

Pfizer to remain aggressive on obesity market after setback

NEW YORK, Jan 8 (Reuters) - Pfizer will remain aggressive in trying to break into the lucrative obesity market, even after dropping a high profile weight-loss drug candidate late last year due to strong side effects, Chief Executive Albert Bourla said on Monday.

Read more
8 Jan 2024 23:00

Pfizer to remain aggressive on obesity market after setback

NEW YORK, Jan 8 (Reuters) - Pfizer will remain aggressive in trying to break into the lucrative obesity market, even after dropping a high profile weight-loss drug candidate late last year due to strong side effects, Chief Executive Albert Bourla said on Monday.

Read more
8 Jan 2024 19:02

Moderna says it hit its 2023 COVID vaccine sales goal

Jan 8 (Reuters) - Moderna on Monday said its 2023 COVID vaccine sales would be around $6.7 billion, coming in above the lower end of its full-year forecast, and reiterated its goal of returning to sales growth in 2025.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.